LEVETIRACETAM, 100mg/ml, 5ml, vial

STD DINJLEVE5V-

Valid Article

Former Code(s): DINJLEVE5A-
The product is supplied (and stored) sterile, it must remain sterile until its use. Sterile = state of being free from all living microorganisms.
Article is intended to be used with children (<12 years) ONLY.
5.1 - Antiseizure medicines
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
N03AX14
Anatomical Therapeutic Chemical Classification according to WHOCC
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   

Add Kit To Wishlist

   

LEVETIRACETAM

Therapeutic Action

Indications

Convulsive status epilepticus in infants, children and pregnant women.

Contact your OC advisor for the treatment protocol.

Instructions for use

Dilute the concentrate solution vial in at least 100 ml of 0.9% NaCl.

Must be given as slow IV infusion.

Levetiracetam can be used as an alternative first-line treatment when phenobarbital is not available.

Injectable valproate sodium can be used as an alternative for epilepsy, in adults only.

Due to the international shortage of injectable phenobarbital and phenytoin, levetiracetam is an alternative for the management of status epilepticus in infants, children, and pregnant women.

Precautions for Use

Do not administer by rapid IV infusion or direct IV injection.

Storage

  • Below 25ºC
  • After dilution, use the solution immediately.
  • Discard any unused open vial.